FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010015820> ?p ?o ?g. }

• W2010015820 endingPage "579" @default.
• W2010015820 startingPage "578" @default.
• W2010015820 abstract "Topiramate is an antiepileptic drug with potentially serious adverse effects. In placebo-controlled trials, myopia was seen in 1% of children and abnormal vision in 13% of adults under the drug. In 2001, postmarketing experience led the US Food and Drug Administration to warn about a new syndrome consisting of acute myopia associated with secondary angle closure glaucoma, and this was added to its labelling. Up to March 2004, the Spanish System of Pharmacovigilance has gathered six reports of myopia and two of glaucoma in eight patients treated with topiramate (see Table 1). In all cases the only suspect medicine was topiramate. Time to onset of symptoms was reported in seven cases; in five the reaction appeared within the first week. All cases of myopia recovered in less than 1 week after drug discontinuation. One patient with glaucoma was operated because initially the role of topiramate was not suspected as the cause. Alternative causes other than topiramate were excluded in most reports. As in previous experiences, these complications occurred early in the course of therapy and they recovered shortly after drug discontinuation [1]. Strikingly, for the six patients for whom the indications for use were known, this was different from epilepsy, which was the only approved indication in Spain until April 2004. The prevalence of epilepsy is low (4–10 per 1000) [2]. In more developed countries, where people are able to pay for new treatments, the prevalence is half that of less developed countries [3], and the majority of patients are already under treatment with one or more antiepileptic drugs. Thus, the market prospects for any pharmaceutical company developing a new antiepileptic drug are limited. Pharmaceutical companies, however, seek market expansion for their products by looking for regulatory approval of additional indications, by involving medical opinion leaders and others in clinical research in new indications, and even by illegally promoting off-label use [4]. Pressure to prescribe concentrates on patent protected medicines. Topiramate is one such drug. Its off-label use made up 14% of the US migraine prophylaxis market [5], before its recent approval for this indication. Monitoring drug safety should not only focus on identifying adverse effects. Pharmacovigilance should be less drug-oriented and more patient-oriented. Had topiramate not been promoted and used for non-approved indications, the patients in the present series would not have developed such serious adverse effects, at the expense of uncertain or absent clinical efficacy in these indications. We thank the reporting physicians and the Centres of Spanish System of Pharmacovigilance. This work was supported by Departament de Salut of the Generalitat de Catalunya." @default.
• W2010015820 created "2016-06-24" @default.
• W2010015820 creator A5024680575 @default.
• W2010015820 creator A5037612015 @default.
• W2010015820 creator A5039733441 @default.
• W2010015820 creator A5074389580 @default.
• W2010015820 date "2005-08-01" @default.
• W2010015820 modified "2023-10-17" @default.
• W2010015820 title "Topiramate in non-approved indications and acute myopia or angle closure glaucoma" @default.
• W2010015820 cites W2011432316 @default.
• W2010015820 cites W2143496876 @default.
• W2010015820 cites W2157979928 @default.
• W2010015820 cites W4235921094 @default.
• W2010015820 cites W4300789829 @default.
• W2010015820 doi "https://doi.org/10.1111/j.1365-2125.2005.02470.x" @default.
• W2010015820 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1884934" @default.
• W2010015820 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16236051" @default.
• W2010015820 hasPublicationYear "2005" @default.
• W2010015820 type Work @default.
• W2010015820 sameAs 2010015820 @default.
• W2010015820 citedByCount "22" @default.
• W2010015820 countsByYear W20100158202012 @default.
• W2010015820 countsByYear W20100158202013 @default.
• W2010015820 countsByYear W20100158202014 @default.
• W2010015820 countsByYear W20100158202019 @default.
• W2010015820 countsByYear W20100158202021 @default.
• W2010015820 countsByYear W20100158202022 @default.
• W2010015820 countsByYear W20100158202023 @default.
• W2010015820 crossrefType "journal-article" @default.
• W2010015820 hasAuthorship W2010015820A5024680575 @default.
• W2010015820 hasAuthorship W2010015820A5037612015 @default.
• W2010015820 hasAuthorship W2010015820A5039733441 @default.
• W2010015820 hasAuthorship W2010015820A5074389580 @default.
• W2010015820 hasBestOaLocation W20100158202 @default.
• W2010015820 hasConcept C118487528 @default.
• W2010015820 hasConcept C118552586 @default.
• W2010015820 hasConcept C126322002 @default.
• W2010015820 hasConcept C141071460 @default.
• W2010015820 hasConcept C142724271 @default.
• W2010015820 hasConcept C187212893 @default.
• W2010015820 hasConcept C197934379 @default.
• W2010015820 hasConcept C204787440 @default.
• W2010015820 hasConcept C27081682 @default.
• W2010015820 hasConcept C2777683783 @default.
• W2010015820 hasConcept C2778186239 @default.
• W2010015820 hasConcept C2778527774 @default.
• W2010015820 hasConcept C2778715236 @default.
• W2010015820 hasConcept C57658597 @default.
• W2010015820 hasConcept C71924100 @default.
• W2010015820 hasConceptScore W2010015820C118487528 @default.
• W2010015820 hasConceptScore W2010015820C118552586 @default.
• W2010015820 hasConceptScore W2010015820C126322002 @default.
• W2010015820 hasConceptScore W2010015820C141071460 @default.
• W2010015820 hasConceptScore W2010015820C142724271 @default.
• W2010015820 hasConceptScore W2010015820C187212893 @default.
• W2010015820 hasConceptScore W2010015820C197934379 @default.
• W2010015820 hasConceptScore W2010015820C204787440 @default.
• W2010015820 hasConceptScore W2010015820C27081682 @default.
• W2010015820 hasConceptScore W2010015820C2777683783 @default.
• W2010015820 hasConceptScore W2010015820C2778186239 @default.
• W2010015820 hasConceptScore W2010015820C2778527774 @default.
• W2010015820 hasConceptScore W2010015820C2778715236 @default.
• W2010015820 hasConceptScore W2010015820C57658597 @default.
• W2010015820 hasConceptScore W2010015820C71924100 @default.
• W2010015820 hasIssue "5" @default.
• W2010015820 hasLocation W20100158201 @default.
• W2010015820 hasLocation W20100158202 @default.
• W2010015820 hasLocation W20100158203 @default.
• W2010015820 hasLocation W20100158204 @default.
• W2010015820 hasOpenAccess W2010015820 @default.
• W2010015820 hasPrimaryLocation W20100158201 @default.
• W2010015820 hasRelatedWork W1968165247 @default.
• W2010015820 hasRelatedWork W2074860758 @default.
• W2010015820 hasRelatedWork W2118566923 @default.
• W2010015820 hasRelatedWork W2320498337 @default.
• W2010015820 hasRelatedWork W2349217635 @default.
• W2010015820 hasRelatedWork W2351548256 @default.
• W2010015820 hasRelatedWork W2353505721 @default.
• W2010015820 hasRelatedWork W2884631023 @default.
• W2010015820 hasRelatedWork W3197360572 @default.
• W2010015820 hasRelatedWork W53449851 @default.
• W2010015820 hasVolume "60" @default.
• W2010015820 isParatext "false" @default.
• W2010015820 isRetracted "false" @default.
• W2010015820 magId "2010015820" @default.
• W2010015820 workType "article" @default.